Mankind Pharma

Mankind Pharma Limited is an Indian pharmaceutical and healthcare company headquartered in Okhla Phase III, New Delhi. Founded by brothers Ramesh C. Juneja and Rajeev Juneja, the company was incorporated in 1991 and began active commercial operations in 1995. It developed from a small, India-focused medicines business into a broad healthcare platform spanning prescription pharmaceuticals, over-the-counter products, consumer healthcare, diagnostics, active pharmaceutical ingredients, veterinary products, pet care, agritech, and specialty biopharmaceuticals. The company’s early commercial model was built around affordability, mass-market distribution, and penetration of price-sensitive segments, especially in rural and semi-urban India. Its first products included the antibacterial brand Zenflox and the prescription antibiotic Moxikind-CV. These products were positioned at prices below many established competitors, helping Mankind establish a reputation for accessible medicines. Rather than initially competing only in premium urban categories, the company used a large field-force and distribution network to reach doctors, pharmacists, and patients across a wide geographic base. Mankind entered consumer healthcare in 2007, initially emphasizing sexual and reproductive health. This expansion created several of the company’s most recognizable brands. Manforce became a major condom franchise; Prega News developed into a leading pregnancy-detection and pregnancy-care brand; and Unwanted-72 became a prominent emergency-contraception product. The company subsequently broadened its consumer portfolio with brands such as Gas-O-Fast, AcneStar, HealthOK, and related wellness and personal-care products. Its consumer businesses rely heavily on mass media, digital advertising, celebrity endorsements, regional marketing, chemist relationships, e-commerce, and increasingly localized campaigns. Mankind has also expanded through acquisitions and internal diversification. The 2007 acquisition of Magnet Labs supported entry into antipsychotic medicines, while the 2010 acquisition of Longifene added a pediatric appetite-stimulant brand formerly associated with UCB. In 2017, the company established Pathkind Labs to build a diagnostics business. It later entered agritech and pet care, reflecting an effort to use its commercial infrastructure beyond conventional human pharmaceuticals. Research and product development have become increasingly important to the company’s positioning. In 2019, Mankind launched Dydroboon, a dydrogesterone product used in areas including infertility treatment and high-risk pregnancy care. The company has also expanded into chronic therapies, women’s health, respiratory care, dermatology, cardiovascular medicine, gastrointestinal products, diabetes, neurology, and other prescription categories. Its manufacturing and research infrastructure includes numerous Indian production facilities and dedicated R&D centers covering formulation development, analytical work, APIs, biotechnology, and related capabilities. Mankind accelerated its portfolio expansion in 2022. It acquired domestic formulation brands from Panacea Biotec Pharma in India and Nepal, purchased selected respiratory and infant-care brands from Dr. Reddy’s Laboratories, and acquired a majority stake in Ayurvedic and herbal-products company Upakarma Ayurveda. These transactions strengthened the company’s presence in established therapeutic and consumer categories while adding complementary distribution opportunities. In April 2023, Mankind completed an initial public offering consisting primarily of an offer for sale by existing shareholders. Its equity shares began trading on the National Stock Exchange of India and BSE in May 2023 under the symbol MANKIND. The listing increased the company’s public-market profile while leaving the founding family and other long-term shareholders central to its ownership and governance structure. The company made its largest s…

Mankind Pharma was incorporated in 1991 by brothers Ramesh C. Juneja and Rajeev Juneja and began active operations in 1995. The founders started with a relatively small amount of capital and a compact workforce, initially concentrating on the Indian market and launching products in two states. The company’s early strategy was to address price-sensitive demand through affordable branded generics and a broad sales and distribution network. Its first phase of growth centered on prescription medicines. Products such as Zenflox and Moxikind-CV were introduced as lower-priced alternatives in antibiotic and antibacterial categories. This approach was particularly relevant in rural and semi-urban markets, where treatment affordability and medicine availability were major commercial considerations. Mankind’s growth depended not only on manufacturing and product selection but also on its ability to place medical representatives and distribution partners close to doctors, pharmacies, and patients. In 2007, the company entered the over-the-counter segment. Sexual healthcare became an early focus, providing the basis for the later expansion of Manforce and other consumer brands. The same year, Mankind acquired Magnet Labs Private Limited, supporting entry into antipsychotic medicines. In January 2010, it acquired Longifene, a pediatric appetite-stimulant brand previously associated with UCB. These moves showed an emerging willingness to combine organic product development with acquisitions of established brands. During the 2010s, Mankind built a more diversified therapeutic platform. Its prescription portfolio expanded into gastrointestinal, cardiovascular, dermatology, diabetes, neurology, respiratory, women’s health, and other categories. At the same time, its consumer healthcare business developed into a major source of brand visibility. Manforce condoms, Prega News pregnancy-test products, and Unwanted emergency contraception became some of the company’s most recognizable offerings. Brands such as Gas-O-Fast, AcneStar, and HealthOK later broadened its presence in wellness, digestive care, dermatology, and personal healthcare. Mankind also invested in adjacent healthcare services. In 2017, it established Pathkind Labs as a diagnostics business, extending its activities beyond medicines into laboratory testing and health screening. The company’s research ambitions became more visible in 2019 when it launched Dydroboon, a dydrogesterone product used in infertility and high-risk pregnancy care. This strengthened Mankind’s position in women’s health and demonstrated its intent to compete in more specialized prescription categories. The company’s manufacturing and R&D capabilities expanded in parallel. By the early 2020s, it operated a large Indian production network covering tablets, capsules, syrups, vials, ampoules, soft and hard gels, eye drops, creams, contraceptives, and other dosage forms. Its R&D infrastructure included dedicated facilities for formulation development, APIs, analytical work, biotechnology, and new drug discovery-related activities. Although exports remained smaller than domestic sales, Mankind developed an international presence in markets across Africa, the Commonwealth of Independent States, Southeast Asia, Nepal, Sri Lanka, and other regions. A significant expansion phase began in 2022. Mankind acquired domestic formulation brands from Panacea Biotec Pharma in India and Nepal. It also acquired selected respiratory and infant-care brands from Dr. Reddy’s Laboratories and purchased a majority stake in Upakarma Ayurveda. In the same period, the company entered agritech and pet care, reflecting a broader consumer and life-sciences strategy rather than a narrow focus on conventional prescription medicines. In April 2023, Mankind launched its initial public offering. The transaction was primarily an offer for sale by existing shareholders rather than a capital-raising issue for the company. The shares were listed on the NSE and BSE in May 2023 under the ticker MANKIND. Public listing increased disclosure requirements and market visibility while the founding family continued to occupy central leadership roles. The most consequential transaction in the company’s history occurred in 2024. Mankind agreed to acquire Bharat Serums and Vaccines from Advent International and completed the acquisition in October of that year. The transaction gave Mankind full ownership of a business with capabilities in women’s health, fertility, critical care, immunoglobulins, recombinant products, niche biologics, and complex drug-delivery systems. More than 2,500 BSV employees joined the combined organization. The acquisition shifted Mankind toward a more balanced mix of high-volume branded generics, consumer products, and higher-barrier specialty pharmaceuticals. Mankind’s current strategy is therefore the result of several overlapping stages: affordable Indian branded generics; consumer-healthcare brand building; expansion into diagnostics and adjacent categories; selective acquisitions; and movement into biologics, fertility, critical care, and other specialized therapies. The company continues to emphasize quality, affordability, accessibility, manufacturing scale, and research-led product development while remaining primarily rooted in the Indian pharmaceutical market.

1. 2024Agreement to acquire Bharat Serums and Vaccines

   Mankind announces an agreement to acquire all shares of Bharat Serums and Vaccines from Advent International.

   Source
2. 2024Bharat Serums and Vaccines acquisition completed

   Mankind completes the acquisition of BSV, adding women’s health, fertility, critical-care, immunoglobulin, and biologics capabilities.

   Source
3. 2023Initial public offering and stock-market listing

   Mankind completes an IPO and begins trading on the NSE and BSE in May 2023.

   Source
4. 2022Panacea Biotec brand acquisition

   Mankind acquires domestic formulation brands from Panacea Biotec Pharma in India and Nepal.

   Source
5. 2022Diversification into agritech and pet care

   The company enters agritech and pet care while continuing to expand its consumer-healthcare activities.

   Source
6. 2019Dydroboon is launched

   Mankind launches Dydroboon, a dydrogesterone product for infertility and high-risk pregnancy-related care.

   Source
7. 2017Pathkind Labs is established

   Mankind establishes Pathkind Labs to build a diagnostics and laboratory-testing business.

   Source
8. 2010Longifene acquisition

   Mankind acquires Longifene, a pediatric appetite-stimulant brand previously associated with UCB.

   Source
9. 2007Entry into over-the-counter healthcare

   Mankind enters the OTC segment, initially emphasizing sexual-health and consumer products.

   Source
10. 2007Magnet Labs acquisition

    The acquisition of Magnet Labs supports Mankind’s entry into antipsychotic medicines.

    Source
11. 1995Commercial operations begin

    The company begins active operations with a small workforce and initially launches products in two Indian states.

    Source
12. 1991Mankind Pharma is incorporated

    Mankind Pharma is incorporated in India by brothers Ramesh C. Juneja and Rajeev Juneja.

    Source

A broad Indian healthcare company built around affordable, accessible medicines and high-volume distribution, with a strong consumer-healthcare presence and an expanding portfolio in women’s health, fertility, specialty pharmaceuticals, diagnostics, and biologics.

• ManforceCondoms and sexual wellness

  Manforce is Mankind Pharma’s flagship condom and sexual-wellness franchise. It includes multiple variants positioned around protection, sensation, fit, endurance, and product experience. The brand became central to Mankind’s OTC strategy and is supported by mass-media, influencer, digital-commerce, and seasonal campaigns. Its marketing has often used direct, humorous, and culturally visible communication to normalize condom conversations and connect the product with safer sex and mutual choice.

• Prega NewsPregnancy detection and pregnancy care

  Prega News is a pregnancy-detection brand that has expanded into a wider pregnancy-care platform. Its core offering is a home pregnancy test, while related extensions and communications address fertility, pregnancy information, emotional support, and the role of partners and families. The brand uses television, digital media, chemist-shop activation, influencer marketing, and partnerships to reach consumers across urban and rural India.

• Unwanted-72Emergency contraception

  Unwanted-72 is Mankind’s emergency-contraception franchise. It is positioned as an accessible, discreet reproductive-health product within the company’s broader women’s-health and sexual-health portfolio. The Unwanted brand family has also included other reproductive-health products, allowing Mankind to cover emergency contraception, pregnancy testing, and related reproductive-care needs through a connected consumer platform.

• Gas-O-FastDigestive and gastrointestinal consumer healthcare

  Gas-O-Fast is a consumer-healthcare franchise focused on digestive discomfort and acidity-related needs. It is sold in convenient formats including sachets and is marketed through broad-reach advertising, sampling, retail activation, and regional campaigns. The product illustrates Mankind’s strategy of building high-recognition OTC brands that can use the company’s extensive chemist, distributor, modern-trade, and e-commerce network.

• AcneStarDermatology and skincare

  AcneStar is Mankind’s dermatology and skincare franchise associated primarily with acne management and related personal-care needs. It sits between prescription-oriented dermatology and consumer skincare, allowing the company to reach both doctor-recommended and self-care audiences. The brand contributes to Mankind’s broader strategy of combining therapeutic credibility with consumer-facing packaging, education, and digital marketing.

• HealthOKVitamins and nutritional supplements

  HealthOK is a consumer-healthcare and nutritional-supplement brand within Mankind’s wellness portfolio. Its products are designed for everyday supplementation and general health support rather than treatment of a single disease. The franchise helps Mankind participate in the expanding vitamins, minerals, supplements, and preventive-wellness market through retail, modern trade, e-commerce, and mass consumer communication.

• NurokindNeurology and vitamin supplementation

  Nurokind is a major prescription brand family associated with vitamin and nerve-health therapies. The range includes multiple formulations and combinations designed for different clinical and supplementation needs. It represents Mankind’s large branded-generic business, in which a recognizable mother brand is extended across strengths, combinations, dosage forms, and physician-led therapeutic uses.

• MoxikindAntibiotics and anti-infectives

  Moxikind is one of Mankind Pharma’s early and best-known prescription franchises. The range includes antibiotic products such as Moxikind-CV and related formulations. Its history reflects the company’s original focus on affordable branded generics and price-sensitive treatment markets. The franchise remains part of the company’s anti-infective and prescription-medicine heritage.

• DydroboonWomen’s health and fertility2019

  Dydroboon is Mankind’s dydrogesterone brand, launched in 2019 for uses including infertility treatment and high-risk pregnancy care. The product strengthened the company’s women’s-health franchise and represented an important move beyond high-volume generics into more specialized reproductive-health therapy. It also created a platform that complemented Mankind’s consumer brands in pregnancy detection and emergency contraception.

• Bharat Serums and Vaccines portfolioBiologics, fertility, women’s health, and critical care

  The Bharat Serums and Vaccines portfolio added biologics and other specialized products to Mankind Pharma following the 2024 acquisition. The acquired business covers women’s health, fertility, critical care, immunoglobulins, emergency medicine, recombinant products, niche biologics, and complex drug-delivery systems. Products and technologies associated with the portfolio include fertility and reproductive-health therapies, Anti-D, Foligraf, Thymogam, and antivenom-related capabilities.

• 2025Prega News Invisible Journey of Fathers

  India

  Prega News used a Father’s Day film to highlight the physical and emotional support provided by expectant fathers while also drawing attention to the less visible difficulties experienced by pregnant women.

  Outcome. The campaign extended Prega News’s brand narrative toward shared parenthood, empathy, and partner support during pregnancy.

  Source
• 2024#CondomNahiManforceBolo

  India

  Manforce collaborated with Dolly Singh on a digital campaign encouraging consumers to associate the generic word “condom” with the Manforce brand. The campaign used humor, influencers, user-generated content, social media, e-commerce, quick-commerce, and product-placement activity.

  Outcome. The year-long campaign was designed to increase brand salience and reinforce Manforce’s claimed leadership in India’s condom segment.

  Source
• 2024Manforce Epic ThinX female-choice campaign

  India

  Manforce promoted its Epic ThinX condom line through a campaign featuring Radhika Apte that emphasized female participation in condom selection, sexual comfort, protection, and informed choice.

  Outcome. The campaign attempted to shift condom communication away from an exclusively male purchasing perspective and toward joint decision-making and women’s sexual-health agency.

  Source
• 2023Prega News chemist and rural-market activation

  India

  Prega News used celebrity-led video, chemist-shop communication, and localized digital advertising to strengthen its relationship with retail chemists and improve visibility around pregnancy testing and care.

  Outcome. The program expanded the brand’s communication from mass advertising toward targeted retail and local digital activation.

  Source
• 2020Real-life support and pandemic initiatives

  India

  During the COVID-19 period, Mankind used corporate and brand communication to recognize healthcare workers, support frontline personnel, and emphasize social solidarity. The company also used regional influencers and digital channels to maintain communication for brands including Manforce, AcneStar, Gas-O-Fast, and Prega News.

  Outcome. The initiatives helped maintain brand visibility while shifting communication toward public support, reassurance, and digital engagement.

  Source
• 2016#YourSecondHome

  India

  Prega News partnered with SpiceJet on an initiative intended to make air travel more comfortable for pregnant women and to position the brand as a supportive presence during pregnancy rather than only a pregnancy-test provider.

  Outcome. The campaign broadened Prega News’s emotional and service-oriented positioning and generated media coverage around pregnancy support.

  Source

• 2024Acquire Bharat Serums and VaccinesM&A

  Mankind aimed to move further into higher-entry-barrier pharmaceuticals and strengthen its position in women’s health, fertility, critical care, immunoglobulins, and biologics.

  What changed. Mankind agreed to acquire and then completed the purchase of 100 percent of Bharat Serums and Vaccines from Advent International.

  Aftermath. The completed transaction added BSV’s specialized product portfolio, R&D platforms, manufacturing capabilities, and more than 2,500 employees to Mankind.

  Purchase consideration. Approximate enterprise value of INR 13,630 crore at announcement → Purchase consideration of approximately INR 13,768.22 crore at completion (July to October 2024)

  Source
• 2023Complete the initial public offeringOther

  Mankind sought a public-market listing after years of privately held growth, giving existing shareholders liquidity and creating a listed platform for future expansion.

  What changed. The company launched an IPO consisting primarily of an offer for sale by promoter and investor shareholders, followed by listings on the NSE and BSE.

  Aftermath. Mankind became a publicly traded Indian pharmaceutical company, increasing reporting obligations, investor visibility, and access to public-market capital over time.

  Offer size. INR 4,326.355 million (2023 IPO)

  Source
• 2022Acquire Panacea Biotec domestic formulation brandsM&A

  Mankind wanted to accelerate prescription-portfolio expansion through established brands and deepen its presence in India and Nepal.

  What changed. Mankind acquired Panacea Biotec Pharma’s domestic formulation brands in India and Nepal.

  Aftermath. The acquisition added established products and supported the company’s strategy of combining organic growth with portfolio acquisitions.

  Purchase consideration. INR 1,872 crore (2022 transaction announcement)

  Source
• 2022Acquire selected Dr. Reddy’s consumer and respiratory brandsM&A

  Mankind pursued established products that could be integrated into its prescription, respiratory, dermatology, and consumer-healthcare distribution network.

  What changed. The company acquired selected respiratory and infant-care brands from Dr. Reddy’s Laboratories.

  Aftermath. The transaction broadened Mankind’s category coverage and added products with existing market recognition.

  Source
• 2019Launch Dydroboon in women’s healthProduct launch

  Mankind identified women’s health, infertility, and pregnancy-related treatment as strategic therapeutic areas with opportunities for branded prescription products.

  What changed. The company launched Dydroboon, a dydrogesterone product for infertility and high-risk pregnancy-related care.

  Aftermath. The launch strengthened Mankind’s women’s-health franchise and complemented its consumer reproductive-health brands.

  Source
• 2017Create a diagnostics platform through Pathkind LabsStrategy

  Mankind sought to expand beyond medicines and participate in health testing and laboratory services.

  What changed. The company established Pathkind Labs as a diagnostics and healthcare-testing business.

  Aftermath. Pathkind gave Mankind an adjacent healthcare-services platform and broadened its relationship with patients and healthcare providers.

  Source
• 2007Enter the over-the-counter and sexual-health marketStrategy

  Mankind’s initial business was centered on prescription branded generics and price-sensitive medicines. The company identified consumer healthcare, particularly sexual health, as an opportunity to build nationally visible brands and diversify revenue.

  What changed. Mankind entered the OTC segment and developed a consumer portfolio that eventually included Manforce, Prega News, and Unwanted.

  Aftermath. The move created some of the company’s most recognizable franchises and gave Mankind a stronger direct-to-consumer marketing identity.

  Source

• 2025Prega News launches a Father’s Day campaign

  Prega News ran a campaign recognizing the practical and emotional contribution of expectant fathers during pregnancy, extending the brand’s communication beyond pregnancy-test detection toward broader pregnancy support.

  Campaign
  Source
• 2024Mankind completes acquisition of Bharat Serums and Vaccines

  Mankind completed the purchase of 100 percent of Bharat Serums and Vaccines, materially increasing its presence in women’s health, fertility, critical care, immunoglobulins, and complex biologics.

  M&A
  Source
• 2023Mankind Pharma launches its initial public offering

  Mankind launched an IPO in April 2023, with existing shareholders offering shares for sale. The company’s equity began trading on the NSE and BSE in May 2023.

  Other
  Source
• 2022Mankind acquires Panacea Biotec domestic brands

  The company acquired Panacea Biotec Pharma’s domestic formulation brands in India and Nepal, expanding its established prescription portfolio.

  M&A
  Source
• 2022Mankind expands through Dr. Reddy’s brand acquisition

  Mankind acquired selected respiratory and infant-care brands from Dr. Reddy’s Laboratories, adding products in complementary therapeutic and consumer categories.

  M&A
  Source
• 2022Mankind buys a majority stake in Upakarma Ayurveda

  The company entered the Ayurvedic and herbal-products market through a majority investment in Upakarma Ayurveda.

  M&A
  Source
• 2019Mankind launches Dydroboon

  Mankind launched Dydroboon, its dydrogesterone product for applications including infertility treatment and high-risk pregnancy care.

  Product launch
  Source
• 2017Mankind establishes Pathkind Labs

  Mankind created Pathkind Labs to develop a diagnostics and healthcare-testing business alongside its pharmaceutical operations.

  Other
  Source
• 2007Mankind enters the over-the-counter healthcare segment

  The company entered over-the-counter healthcare, initially emphasizing sexual-health and consumer products that later became important parts of its brand portfolio.

  Product launch
  Source
• 1995Mankind Pharma begins operations after incorporation

  Following its 1991 incorporation, Mankind Pharma began active operations with a small workforce and an initial focus on affordable medicines in two Indian states.

  Other
  Source

1. Mankind Pharma
2. Mankind Pharma corporate overview
3. Mankind Pharma annual reports and investor information
4. Mankind Pharma IPO prospectus
5. Mankind Pharma IPO basis of allotment
6. Mankind Pharma agreement to acquire Bharat Serums and Vaccines
7. Mankind Pharma completion of Bharat Serums and Vaccines acquisition
8. Competition Commission of India approval of the BSV acquisition
9. Mankind Pharma Manforce campaign with Dolly Singh
10. Mankind Pharma Prega News Father’s Day campaign
11. Panacea Biotec brand acquisition
12. #YourSecondHome
13. Real-life support and pandemic initiatives
14. Prega News chemist and rural-market activation
15. Manforce Epic ThinX female-choice campaign
16. Acquire selected Dr. Reddy’s consumer and respiratory brands
17. Mankind buys a majority stake in Upakarma Ayurveda